Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

7.7%

2 terminated/withdrawn out of 26 trials

Success Rate

89.5%

+2.9% vs industry average

Late-Stage Pipeline

42%

11 trials in Phase 3/4

Results Transparency

59%

10 of 17 completed trials have results

Key Signals

3 recruiting10 with results

Enrollment Performance

Analytics

Phase 3

9(40.9%)

N/A

7(31.8%)

Phase 2

2(9.1%)

Phase 1

2(9.1%)

Phase 4

2(9.1%)

22Total

Phase 3(9)

N/A(7)

Phase 2(2)

Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials

NCT05267613Phase 3Active Not Recruiting

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

Role: collaborator

NCT07637734Phase 3Not Yet Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

Role: collaborator

NCT07457918Phase 3Recruiting

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Role: collaborator

NCT06639828Phase 4Recruiting

Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging

Role: collaborator

NCT07246590Phase 3Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Role: collaborator

NCT04763512Not ApplicableCompleted

Clinical Study of Partially Hydrolysed Protein Infant Formula on Trans-epidermal Water Loss (TEWL)

Role: collaborator

NCT00981058Phase 3Completed

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Role: collaborator

NCT05054309Not ApplicableCompleted

A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

Role: collaborator

NCT01110460Completed

Prospective Study on Asthma Control

Role: collaborator

NCT03714815Phase 2Terminated

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Role: collaborator

NCT04078152Phase 4Completed

Durvalumab Long-Term Safety and Efficacy Study

Role: collaborator

NCT04201132Not ApplicableActive Not Recruiting

Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System

Role: collaborator

NCT04566653Completed

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

Role: collaborator

NCT03775421Phase 3Terminated

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

Role: collaborator

NCT00982111Phase 3Completed

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Role: collaborator

NCT02586155Phase 3Completed

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

Role: collaborator

NCT02697916Not ApplicableCompleted

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

Role: collaborator

NCT04699643Phase 1Unknown

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Role: collaborator

NCT01007032Phase 1Completed

A Study of IMC-A12 in Advanced Solid Tumors

Role: collaborator

NCT01148329Completed

PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study

Role: collaborator